Xenocor

Executive Summary

Xenocor is a privately held medical device company headquartered in San Diego, California, but originally founded in Salt Lake City, Utah. The company specializes in developing and commercializing single-use laparoscopic imaging systems for surgical applications. Its flagship product, the Saberscope™, is a 1080 HD single-use laparoscope designed to enhance surgical visualization, minimize infection risks, and reduce operational complexity compared to reusable alternatives. Despite initial classification as a biotech firm, Xenocor operates strictly within the surgical device sector. The company has not disclosed funding rounds or valuation, and its stage of development remains unclear from public sources. However, its focus on single-use devices aligns with growing trends in infection control and operational efficiency in healthcare. With limited public information, Xenocor appears to be in early commercialization or pre-revenue stage, targeting a niche market within laparoscopy. The executive summary is based on the limited data available, and the company's potential hinges on successful market adoption of the Saberscope™.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance or CE mark for Saberscope™70% success
• Q1 2027First commercial contract with a hospital or surgical center50% success
• Q2 2027Series A funding round announcement60% success